EA202191107A1 - T-клеточные рецепторы ny-eso-1 и способы их применения - Google Patents

T-клеточные рецепторы ny-eso-1 и способы их применения

Info

Publication number
EA202191107A1
EA202191107A1 EA202191107A EA202191107A EA202191107A1 EA 202191107 A1 EA202191107 A1 EA 202191107A1 EA 202191107 A EA202191107 A EA 202191107A EA 202191107 A EA202191107 A EA 202191107A EA 202191107 A1 EA202191107 A1 EA 202191107A1
Authority
EA
Eurasian Patent Office
Prior art keywords
eso
cell receptors
methods
application
tcrs
Prior art date
Application number
EA202191107A
Other languages
English (en)
Inventor
Роберт Бабб
Натали Бауэрман
Ган Чэнь
Каган ГУРЕР
Джоанна Хансен
Вэнь-И Ли
Томас Мигер
Дэвид Сух
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202191107A1 publication Critical patent/EA202191107A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Данное изобретение относится к выделенным Т-клеточным рецепторам (TCR), которые специфически связываются с пептидами плоскоклеточной карциномы пищевода 1 типа Нью-Йорк (NY-ESO-1), экспонируемыми HLA, а также к терапевтическим и диагностическим способам применения этих выделенных TCR.
EA202191107A 2018-10-23 2019-10-23 T-клеточные рецепторы ny-eso-1 и способы их применения EA202191107A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862749194P 2018-10-23 2018-10-23
PCT/US2019/057543 WO2020086647A1 (en) 2018-10-23 2019-10-23 Ny-eso-1 t cell receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202191107A1 true EA202191107A1 (ru) 2021-09-17

Family

ID=68582342

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191107A EA202191107A1 (ru) 2018-10-23 2019-10-23 T-клеточные рецепторы ny-eso-1 и способы их применения

Country Status (10)

Country Link
US (1) US20210403527A1 (ru)
EP (1) EP3870602A1 (ru)
JP (1) JP2022505679A (ru)
KR (1) KR20210093908A (ru)
CN (1) CN113454110A (ru)
AU (1) AU2019364367A1 (ru)
CA (1) CA3117539A1 (ru)
EA (1) EA202191107A1 (ru)
MA (1) MA53981A (ru)
WO (1) WO2020086647A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
US20230250149A1 (en) * 2020-06-25 2023-08-10 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022183076A1 (en) * 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Enhanced immune cell therapy targeting ny-eso-1
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN113912701A (zh) * 2021-10-14 2022-01-11 深圳大学总医院 Tcr及其在诊断/治疗中的应用
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
WO2023114433A1 (en) * 2021-12-15 2023-06-22 3T Biosciences, Inc. Methods and systems for assessing immune cell receptors and antigens
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023141587A2 (en) * 2022-01-20 2023-07-27 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
EP0378576B1 (en) 1987-09-11 1995-01-18 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
DE68927996T2 (de) 1988-02-05 1997-12-04 Whitehead Biomedical Inst Modifizierte hepatozyten und deren anwendung
CA2095256A1 (en) 1990-10-31 1992-05-01 Brad Guild Retroviral vectors useful for gene therapy
EA200001216A1 (ru) 1998-05-19 2001-06-25 Авидекс Лимитед Растворимый т-лимфоцитный рецептор
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ATE373078T1 (de) 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
WO2014160030A2 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
EP3015477B1 (en) * 2013-06-26 2021-08-18 XLifeSc, Ltd. High-stability t-cell receptor and preparation method and application thereof
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
CN117143814A (zh) 2014-11-17 2023-12-01 阿迪塞特治疗公司 工程化的γδ T细胞
CN105985427A (zh) * 2015-02-06 2016-10-05 广州市香雪制药股份有限公司 高亲和力ny-eso t细胞受体
PT3280257T (pt) 2015-04-06 2023-09-12 Regeneron Pharma Respostas imunes mediadas por células t humanizadas em animais não humanos
CN106188275A (zh) * 2015-05-06 2016-12-07 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的t细胞受体
CN106432475B (zh) * 2015-10-19 2018-06-01 广东香雪精准医疗技术有限公司 高亲和力ny-eso t细胞受体
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
CN108456247A (zh) * 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途

Also Published As

Publication number Publication date
CA3117539A1 (en) 2020-04-30
AU2019364367A1 (en) 2021-05-27
KR20210093908A (ko) 2021-07-28
US20210403527A1 (en) 2021-12-30
WO2020086647A8 (en) 2020-05-28
JP2022505679A (ja) 2022-01-14
MA53981A (fr) 2021-09-01
EP3870602A1 (en) 2021-09-01
CN113454110A (zh) 2021-09-28
WO2020086647A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
EA202191107A1 (ru) T-клеточные рецепторы ny-eso-1 и способы их применения
EA201991696A1 (ru) Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
EA202092436A1 (ru) Противораковые соединения, нацеливающие на ядерные гормональные рецепторы
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
CY1121962T1 (el) Υποδοχεις τ κυτταρου
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
BR112018067458A2 (pt) anticorpos para tigit
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CO2019010524A2 (es) Plataforma de identificación de péptidos inmunogénicos basada en población
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA202090149A1 (ru) Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
EA201691323A1 (ru) Анти-vista антитела и фрагменты
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA202090296A1 (ru) Спироциклические соединения и способы их получения и применения
EA201891799A1 (ru) Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda
AR115963A1 (es) Anticuerpos anti-il1rap y métodos de uso de estos
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.
EA201892716A1 (ru) Антитела к фактору свертывания xi